BActinium-1: A Phase 1b, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Intravenous Administration of B7-H3 Radiopharmaceutical ([225Ac]Ac-AKY-2519) in Metastatic Castration-Resistant Prostate Cancer
Latest Information Update: 21 May 2026
At a glance
- Drugs Actinium-225 AKY 2519 (Primary) ; Copper 64 AKY 2519 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- Acronyms BActinium-1
- Sponsors Aktis Oncology
Most Recent Events
- 04 May 2026 According to Aktis Oncology media release, the trial has been initiated. The preliminary data anticipated in the first quarter of 2027.
- 04 May 2026 Status changed from planning to recruiting.
- 21 Apr 2026 According to Aktis Oncology media release, data from this trial will be presented in two poster presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 29 to June 2, 2026, in Chicago.